



FOR IMMEDIATE RELEASE

**OriGene and Tanox Establish Research Collaboration**  
*Large-scale functional genomics study of 2,000 genes planned*

Rockville, MD. October 8, 2003 – OriGene Technologies Inc today announced a research collaboration with Tanox Inc (NASDAQ TNOX) for the functional study of 2,000 full-length human cDNA clones encoding membrane bound proteins. Tanox will reserve the rights for therapeutic applications identified through this collaboration. OriGene will retain the rights for research and diagnostic reagent development.

OriGene Technologies, a research tool provider for functional gene discovery, has utilized high-throughput cloning and expression profiling to isolate and catalog a searchable gene bank of 20,000 full-length human cDNA clones suitable for transfection and direct *in vitro* expression. Tanox, a biopharmaceutical company, is engaged in the discovery and development of therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.

OriGene full-length genes are unidirectionally cloned from reverse-transcribed human cDNA libraries into industry-standard mammalian expression vectors. CDNA inserts are never subjected to PCR amplification, thereby avoiding random mutation and eliminating downstream experimental deviation.

"OriGene has distinguished itself from other clone providers through its commitment and ability to providing the most comprehensive human gene collection of the highest quality," said Karl Kovacs PhD, Senior Director of Operations at OriGene. "Our collaboration with Tanox is a testament that such quality is essential for research and valued by the scientific community."

**About OriGene Technologies**

OriGene Technologies is a research tool provider for functional gene discovery that utilizes high-throughput gene cloning and gene expression profiling to develop commercially available products for pharmaceutical, biotechnology, and academic research and discovery applications. Committed to this mission since 1996, OriGene has created the TrueClone™ Collection – a searchable gene bank of 20,000 human full-length cDNA clones suitable for transfection and direct *in vitro* expression. Additional products and services include Blue-Ribbon™ Gene Expression Reagents for RNA and functional gene analysis and Rapid-Screen™ Tools for cDNA screening and full-length gene isolation. More information about OriGene Technologies and their products can be found on the company's web site at <http://www.origene.com>

Contact: Karl Kovacs PhD  
Director of Operations  
Phone: 240-620-0238  
Email: [kkovacs@origene.com](mailto:kkovacs@origene.com)